Efficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: Experience of two pediatric institutions

References

• Pui C-H, Horward S C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257–268
   PubMed Web of Science ®Google Scholar
• Vilmer E, Suciu S, Ferster A, Bertrand Y, Cavè H, Thyss A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukaemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257–2266
   PubMed Web of Science ®Google Scholar
• Pui C-H. Toward optimal central nervous system-directed treatment in childhood acute lymphoblastic leukaemia. J Clin Oncol 2003; 21: 179–181
   PubMed Web of Science ®Google Scholar
• Bürger B, Zimmermann M, Mann G, Kühl J, Löning L, Riehm H, et al. Diagnostic cerebrospinal fluid (CSF) examination in children with acute lymphoblastic leukemia (ALL): significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003; 21: 184–188
   PubMed Web of Science ®Google Scholar
• Conter V, Schrappe M, Aricò M, Reiter A, Dördelmann M, Valsecchi M G, et al. Role of cranial radiotherapy for childhood T-cell lymphoblastic leukaemia with high WBC count and good response to prednisone. J Clin Oncol 1997; 15: 2786–2791
   PubMed Web of Science ®Google Scholar
• Murry D J, Blaney S M. Clinical pharmacology of endocapsulated sustained-release cytarabine. Ann Pharmacother 2000; 34: 1173–1178
   PubMed Web of Science ®Google Scholar
• Bomgaars L, Geyer J R, Franklin J, Dahl G, Park J, Winick N J, et al. Phase I trial of intrathecal liposomal Cytarabine in children with neoplastic meningitis. J Clin Oncol 2004; 22: 3916–3921
   PubMed Web of Science ®Google Scholar
• Sancho J M, Ribera J M, Romero M J, Martin-Reina V, Giraldo Pilar, Ruiz E. Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukaemia: report of 6 cases. Haematologica 2006; 91: e3–e5
   Google Scholar
• Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphoblastic leukaemia. Blood 2007; 109: 3214–3218
   PubMed Web of Science ®Google Scholar
• Chamberlain M C, Glantz M J. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphoblastic leukaemia. Blood 2007; 110: 1698
   PubMed Web of Science ®Google Scholar
• Pui C-H. Toward optimal use of intrathecal liposomal cytarabine. Leuk Lymphoma 2007; 48: 1672–1673
   PubMed Web of Science ®Google Scholar
• McClune B, Buadi F K, Aslam N, Przepiorka D. Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphoblastic leukaemia and high-grade lymphoma. Leuk Lymphoma 2007; 48: 1849–1851
   PubMed Web of Science ®Google Scholar
• Benesch M, Sovinz P, Krammer B, Lackner H, Mann G, Schwinger W, et al. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis. J Pediatr Hematol Oncol 2007; 26: 222–226
   Web of Science ®Google Scholar
• National Cancer Institute. Guidelines for Reporting of Adverse Drugs Reactions. Divisions of Cancer Treatment, National Cancer Institute, Bethesda, MD 1988
   Google Scholar
• Flohr T, Scrauder A, Cazzaniga G, Panzer-Grumayer R, van der Velden V, Fisher S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia. Leukemia 2008; 22: 771–782
   PubMed Web of Science ®Google Scholar
• Aricò M, Valsecchi M G, Rizzari C, Barisone E, Biondi A, Casale F, et al. Long-term results of the AIEOP-ALL-95 trial for childhood acute lymphoblastic leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster-based chemotherapy. J Clin Oncol 2008; 26: 283–289
   PubMed Web of Science ®Google Scholar
• Uderzo C, Conter V, Dini G, Locatelli F, Miniero R, Tamaro P. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Haematologica 2001; 86: 1–7
   PubMed Web of Science ®Google Scholar
• Rivera G K, Hudson M M, Liu Q, Benaim E, Ribeiro R C, Crist W M, et al. Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia. Blood 1996; 88: 831–837
   PubMed Web of Science ®Google Scholar
• Ochs J J, Rivera G, Aur R J, Hustu H O, Berg R, Simone J V. Central nervous system morbidity following an initial isolated central nervous system relapse and its subsequent therapy in childhood acute lymphoblastic leukemia. J Clin Oncol 1985; 3: 622–626
   PubMed Web of Science ®Google Scholar
• Vezmar S, Becker A, Bode U, Jaehde U. Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003; 49: 92–104
   PubMed Web of Science ®Google Scholar
• Resar L M, Phillips P C, Kastan M B, Leventhal B G, Bowman P W, Civin C I. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukaemia of B-cell type. Cancer 1993; 71: 117–123
   PubMed Web of Science ®Google Scholar